Accelerated approval for Keytruda as combo for NSCLC

11th May 2017 Uncategorised 0

The US Food and Drug Administration has issued an accelerated approval for Merck & Co’s immunotherapy Keytruda in combination with pemetrexed (Eli Lilly’s Alimta) and carboplatin for the first-line treatment of metastatic nonsquamous non-small cell lung cancer.

More: Accelerated approval for Keytruda as combo for NSCLC
Source: News